WALTHAM, Mass., Dec. 10, 2013 /PRNewswire/ -- Is there anything more frustrating than waking up in the middle of a nice dream? Awakening in the middle of the night can negatively affect one's mood the next day. It's one thing to be roused by an alarm clock or persistent pet that wants to be fed or walked, but being jolted out of sleep by agonizing leg pain is another story. Unfortunately, many of those who suffer from a condition called Painful Diabetic Neuropathy (PDN) are all too familiar with this occurrence.
PDN affects many people with diabetes. They might experience burning, stabbing or shooting pains in the feet or legs, especially when trying to sleep. The pain is often so severe it either makes falling sleep impossible or wakes them up.
Luckily, a company called NeuroMetrix, Inc. has recognized the need for a treatment that will work while the patient sleeps. NeuroMetrix is a Waltham, MA-based medical device company that develops and markets tests and therapies for diabetic neuropathies. They have developed the SENSUS™ Pain Management System, an innovative new device to provide relief to those suffering from chronic diabetes pain. As Shai Gozani, President and CEO of NeuroMetrix, reports, "People often describe the pain to be like walking on a bed of nails or feeling like their feet are on fire. SENSUS may help relieve that pain."
One of the best parts about SENSUS is that it's lightweight and discreet. Wrapping around the patient's calf, it can be worn right under clothing. Its easy one-button control makes it the ideal solution for PDN sufferers of any age. It is non-addictive, non-narcotic, free of side effects and provides pain relief even during sleep. SENSUS is also the first transcutaneous electrical nerve stimulator cleared by the U.S. Food and Drug Administration to be used while sleeping. In addition to its pain relief benefits, should SENSUS become dislodged from the skin for any reason, it immediately shuts off.
For more information, visit www.SENSUSRx.com, who paid for the writing and dissemination of this release.
Contact: Laura Radocaj, Dian Griesel Int'l.
SOURCE NeuroMetrix, Inc.